Literature DB >> 22024309

Guiding patients facing decisions about "futile" chemotherapy.

Erin Alesi, Barton Bobb, Thomas J Smith.   

Abstract

Ms. G is a 71-year-old woman with metastatic gastric adenocarcinoma recently diagnosed after an extensive surgical resection for a small bowel obstruction (SBO). She was admitted from the surgery clinic with intractable nausea and vomiting. An abdominal computerized tomographic (CT) scan revealed a partial SBO and peritoneal carcinomatosis. Given her recent surgery, the extent of her disease, and high likelihood of recurrent SBO, the surgical team decided that Ms. G was no longer a surgical candidate. When her symptoms did not improve with conservative measures, both oncology and palliative medicine were consulted to assist with symptom management and goals of care. The oncology team stated that Ms. G was still a chemotherapy candidate and suggested that she attend her new patient evaluation in oncology clinic the following week. The palliative medicine team then met with the patient to discuss management options and her preferences for care. The palliative care team explained ways to control her nausea and vomiting without using a nasogastric tube, and the patient agreed to transfer to their service for symptom management. The palliative team explained that her cancer was incurable but that chemotherapy options existed to help control her disease and possibly prolong her life. They also explained that the chemotherapy has side effects and that the patient would need to decide if she wanted to undergo treatment and accept potential side effects for the possibility of prolonging her life by weeks to months and improving her symptoms. As an alternative, she was told that she could focus solely on symptom control with medications and allow her disease to take its natural course. Ms. G was asked to think about how she wanted to spend the time she had left. Prior to discharge, as her symptoms improved, Ms. G was evaluated by another oncologist, who, after consulting the expert gastrointestinal cancer team, explained to her that the current chemotherapy options available for metastatic gastric cancer were rarely, if ever, successful at reversing malignant obstruction. With this information, the patient decided to be discharged home with hospice and spend time with her family. She died peacefully at her home approximately two weeks later. Copyright Â
© 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22024309      PMCID: PMC3205415          DOI: 10.1016/j.suponc.2011.04.001

Source DB:  PubMed          Journal:  J Support Oncol        ISSN: 1544-6794


  14 in total

1.  The rise and fall of the futility movement.

Authors:  P R Helft; M Siegler; J Lantos
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

2.  Early palliative care for patients with metastatic non-small-cell lung cancer.

Authors:  Jennifer S Temel; Joseph A Greer; Alona Muzikansky; Emily R Gallagher; Sonal Admane; Vicki A Jackson; Constance M Dahlin; Craig D Blinderman; Juliet Jacobsen; William F Pirl; J Andrew Billings; Thomas J Lynch
Journal:  N Engl J Med       Date:  2010-08-19       Impact factor: 91.245

3.  Giving honest information to patients with advanced cancer maintains hope.

Authors:  Thomas J Smith; Lindsay A Dow; Enid Virago; James Khatcheressian; Laurel J Lyckholm; Robin Matsuyama
Journal:  Oncology (Williston Park)       Date:  2010-05       Impact factor: 2.990

Review 4.  Medical futility: its meaning and ethical implications.

Authors:  L J Schneiderman; N S Jecker; A R Jonsen
Journal:  Ann Intern Med       Date:  1990-06-15       Impact factor: 25.391

5.  Development and evaluation of a decision aid for patients considering first-line chemotherapy for metastatic breast cancer.

Authors:  Kimberly S Chiew; Heather Shepherd; Janette Vardy; Martin H N Tattersall; Phyllis N Butow; Natasha B Leighl
Journal:  Health Expect       Date:  2008-03       Impact factor: 3.377

6.  A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

Authors:  E Massarelli; F Andre; D D Liu; J J Lee; M Wolf; A Fandi; J Ochs; T Le Chevalier; F Fossella; R S Herbst
Journal:  Lung Cancer       Date:  2003-01       Impact factor: 5.705

7.  Impact of an inpatient palliative care team: a randomized control trial.

Authors:  Glenn Gade; Ingrid Venohr; Douglas Conner; Kathleen McGrady; Jeffrey Beane; Robert H Richardson; Marilyn P Williams; Marcia Liberson; Mark Blum; Richard Della Penna
Journal:  J Palliat Med       Date:  2008-03       Impact factor: 2.947

8.  Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. American Society of Clinical Oncology.

Authors: 
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

9.  Increased satisfaction with care and lower costs: results of a randomized trial of in-home palliative care.

Authors:  Richard Brumley; Susan Enguidanos; Paula Jamison; Rae Seitz; Nora Morgenstern; Sherry Saito; Jan McIlwane; Kristine Hillary; Jorge Gonzalez
Journal:  J Am Geriatr Soc       Date:  2007-07       Impact factor: 5.562

10.  Comparing hospice and nonhospice patient survival among patients who die within a three-year window.

Authors:  Stephen R Connor; Bruce Pyenson; Kathryn Fitch; Carol Spence; Kosuke Iwasaki
Journal:  J Pain Symptom Manage       Date:  2007-03       Impact factor: 3.612

View more
  1 in total

1.  Outcomes of Inpatient Administration of Restricted Antineoplastic Medications at a Large Academic Medical Institution.

Authors:  Kimberly M Lau; Katrina Derry; Ashley Dalton; Janine Martino
Journal:  P T       Date:  2019-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.